Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-302 with Cadonilimab and Capecitabine in CLDN18.2+ Gastric Cancer
NCT06587425Phase 2Recruiting
- Sponsor
- Zhongshan Hospital, Fudan University
- Start
- Jul 2024
- Primary completion
- Jul 2025
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of tpx-4589 in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by Zhongshan Hospital, Fudan University. Started Jul 2024; status: recruiting.
02
Drugs
tpx-4589
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT06587425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06587425.